In reply
We wish to thank Lavoie and colleagues for their thoughtful letter. We agree with their suggestion that interventions in behavioral medicine be viewed analogously to phase 1, 2, and 3 clinical trials in drug development and thank them for pointing out the recommendations of the Office of Behavioral and Social Science Research.